Artificial intelligence is generating an unprecedented number of potential drug candidates, overwhelming traditional validation processes in the pharmaceutical industry.
10x Science, a new biotech startup, is tackling this bottleneck with an AI-powered platform designed to efficiently characterize and prioritize viable molecules.
Seed Funding Fuels Rapid Growth
The company announced a $4.8 million seed round led by Initialized Capital, with participation from Y Combinator, Civilization Ventures, and Founder Factor.
Founded in December 2025 by biochemists David Roberts and Andrew Reiter, alongside AI expert Vishnu Tejas, 10x Science draws on their experience from Stanford's Nobel-winning lab.
The platform integrates deterministic algorithms from chemistry and biology with AI agents to analyze complex data from mass spectrometry.
Roberts explained, "You can add as many candidates as you want to the top of the funnel, but they all have to pass through this characterization process."
A scientist at client Rilas Technologies praised the tool for autonomously identifying proteins and delivering quick, traceable insights.
Historical Context and Industry Challenges
Since Google DeepMind's protein structure prediction model earned the 2024 Nobel Prize in Chemistry, AI has exploded the volume of drug ideas but strained downstream testing.
Traditional mass spectrometry analysis is accurate yet slow and expertise-heavy, creating barriers for smaller researchers and even big pharma.
Looking ahead, 10x Science plans to hire engineers, refine its SaaS model, and expand to integrate protein data with broader cellular insights for a "new way to define molecular intelligence."
Investors see it as essential infrastructure for biopharma, independent of any single drug's success, poised to democratize advanced drug validation.
Andrew Lee
